Abstract:
An object is to provide a TCR closing system that enables not only bias-free analysis of TCR repertoires, but also collection of antigen-specific TCR α/β cDNA pairs and evaluation of functions thereof. There is provided a method for producing a gene of T cell receptor (TCR) specific to an antigen A, which comprises 1) the step of stimulating a group of T cells including a T cell specific to an antigen A or one T cell specific to an antigen A under a condition effective for amplification of a TCR gene; 2) the step of identifying a T cell specific to an antigen A among the group of T cells including a T cell specific to the antigen A, and sorting one T cell specific to the antigen A into a vessel; and 3) the step of subjecting the one activated T cell specific to the antigen A in the vessel to PCR to amplify a gene of TCR specific to the antigen A. According to the present invention, a target TCR gene can be cloned within a shorter time compared with that repaired by the conventional methods, for example, about ten days. Further, according to the present invention, genes of TCR α chain and β chain can be highly efficiently cloned. Under the conditions of the examples, a pair of a TCR α chain and TCR β chain could be obtained from stimulated T cells sorted as single cells at a ratio of 100%.
Abstract:
A three-dimensional guide for a wire for forming a pedicle screw insertion hole is produced based on a CT image of a spine, and includes a contact surface section that comes in surface contact with a morphological surface of a bone at an insertion site, and a guide block section that is provided upright from the contact surface section. The guide block section has a guide hole that restricts the insertion direction of the wire. The guide hole has an inner diameter slightly larger than the outer diameter of the wire. The guide hole has a length of 15 to 30 mm to restrict the insertion position and the insertion direction of the wire.
Abstract:
To ensure that a biodegradable medical implement dissolves in vivo at an appropriate dissolution rate. The biodegradable medical implement of the present invention is formed of a magnesium material, and, at least in one transverse section, a layer of magnesium crystal grains in which a (0001) plane in a hexagonal crystal structure is oriented toward a surface side is continuous over an entire circumference.
Abstract:
A hydrocarbon synthesis catalyst is for reacting a raw material gas including hydrogen and carbon dioxide to convert to hydrocarbons, wherein when elemental analysis of a surface of the hydrocarbon synthesis catalyst to be brought into contact with the raw material gas is performed by energy dispersive X-ray spectroscopy (SEM-EDX), 15 to 65% by mass of Fe, 10 to 40% by mass of O, 0.04 to 30% by mass of Na, 0 to 15% by mass of Ni, and 5 to 30% by mass of Cr are detected.
Abstract:
The present invention addresses the problem of providing a wound contact member (or “contact layer”) that directly promotes wound healing when continuously performing negative pressure wound therapy (NPWT). As a solution, there is provided dry amniotic membrane manufactured by a specified drying process, that is, raw amniotic membrane placed inside a processing tank (10) is continuously heated using an infrared heater (14) provided inside the processing tank (10) while performing a depressurization operation that places the processing tank in a depressurized state and irradiation of the raw amniotic membrane with microwaves from a microwave generating device (30) provided inside the processing tank (10) to apply energy to water molecules present inside the amniotic membrane and cause drying during a pressure recovery operation that slightly raises the pressure inside the depressurized processing tank (10) toward atmospheric pressure. Amniotic membrane, which has been dried by repeating the above process and thereby retains its cell and tissue structure, is used as a contact layer when performing negative pressure wound therapy (NPWT) on an open abdominal wound and/or wound dehiscence, which increases the healing effect of NPWT.
Abstract:
A magnesium alloy containing Al, Sr, Ca, and Mn, with the balance being Mg and inevitable impurities, the magnesium alloy having: a structure having an α-Mg phase, and a precipitate dispersed in at least one of a grain boundary of the α-Mg phase and a cell boundary, the precipitate including: at least one phase selected from a group A consisting of an Al2Sr phase, an Al4Sr phase, a (Mg, Al)2Sr phase, and a (Mg, Al)4Sr phase; and at least one phase selected from a group B consisting of an Al2Ca phase and a (Mg, Al)2Ca phase, the magnesium alloy having, in a cross section, a total area rate of a group A precipitate and a group B precipitate of greater than or equal to 2.5% and less than or equal to 30%.
Abstract:
A new analgesic has been developed for T-type calcium channels as therapeutic targets.The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.
Abstract:
As a method for highly efficiently amplifying a TCR cDNA in a short period of time, there is provided a method for amplifying a T cell receptor (TCR) cDNA, which comprises the following step (1) and step (2): (1) the step of performing PCR by using at least one kind of the L primer mentioned below, the C primer 1 or UTR primer 1 mentioned below, and cDNA obtained from a single cell as the template to obtain an amplification product 1; an L primer of 30- to 60-nucleotide length comprising an adapter part of 15- to 25-nucleotide length, and a leader region-annealing part of 15- to 25-nucleotide length, which is ligated downstream from the adapter part, and can anneal to a part of a leader region containing a translation initiation codon, or an upstream part thereof, a C primer 1 of 15- to 25-nucleotide length, which can anneal to a part of a constant region, or a UTR primer 1 of 15- to 25-nucleotide length, which can anneal to a part of a 3′ untranslated region; (2) the step of performing PCR by using the adaptor primer mentioned below, the C primer 2 or UTR primer 2 mentioned below, and the amplification product 1 as the template to obtain an amplification product 2; an adapter primer of 15- to 25-nucleotide length, which can anneal to the adapter part of the amplification product 1, a C primer 2 of 15- to 25-nucleotide length, which can anneal to a part of the constant region existing upstream from the region to which the C primer 1 anneals, or a UTR primer 2 of 15- to 25-nucleotide length, which can anneal to a part of the 3′ untranslated region existing upstream from the region to which the UTR primer 1 anneals.
Abstract:
A magnesium alloy is provided that includes: 5.0 mass % or more and 15.0 mass % or less of Al; 2.5 mass % or more and 7.0 mass % or less of Sr; 0.05 mass % or more and less than 3.0 mass % of Ca; and 0.1 mass % or more and 0.6 mass % or less of Mn, with a remainder including Mg and inevitable impurities.
Abstract:
An Al—Mg—Si-based aluminum alloy includes 0.015 to 0.12 mass % of Sr, the aluminum alloy producing a cast metal structure in which Mg2Si is crystallized in a fine agglomerate form.